Target Name: WBP2
NCBI ID: G23558
Review Report on WBP2 Target / Biomarker Content of Review Report on WBP2 Target / Biomarker
WBP2
Other Name(s): WW domain binding protein 2 | WW domain binding protein 2, transcript variant 1 | WW domain-binding protein 2 | DFNB107 | WBP-2 | WBP2 variant 1 | GRAMD6 | WW domain-binding protein 2 (isoform 1) | WBP2_HUMAN | MGC18269

Understanding The Potential of WBP2 as A Drug Target Or Biomarker

World Wide Web Binding Protein 2 (WBP2) is a protein that plays a crucial role in the regulation of the immune system and has been identified as a potential drug target or biomarker. WBP2 is a member of the superfamily of leucine-rich repeat (LRR ) proteins, which are characterized by the presence of a characteristic leucine-rich repeat in their amino acid sequence. WBP2 is expressed in a variety of tissues, including the blood, spleen, and Peyer's patches of the small intestine, and its function is still being fully understood.

One of the unique features of WBP2 is its ability to interact with multiple DNA-protein interfaces, including those in the immune response and inflammation. This interaction between WBP2 and DNA-protein interfaces makes it a promising target for drugs that aim to modulate immune systems and inflammatory processes.

Recent studies have demonstrated that WBP2 plays a critical role in the regulation of T cell development and function. WBP2 has been shown to interact with the transcription factor T-cell factor (TF), which is involved in the regulation of T cell proliferation and differentiation . Additionally, WBP2 has been shown to modulate the activity of the immune regulator PD-1, which is critical for the regulation of T cell immune response.

WBP2 has also been shown to play a role in the regulation of inflammation. Its interaction with nuclear factor kappa B (NFKB), a transcription factor that is involved in the regulation of inflammation, has been identified. This interaction may contribute to the regulation of chronic inflammatory diseases such as autoimmune diseases.

The potential drug targets for WBP2 are vast and varied. One approach is to target WBP2 directly with small molecules, such as inhibitors of WBP2 function, or modulators of its interaction with DNA-protein interfaces. Another approach is to target WBP2 through its downstream targets , such as TF and PD-1, with the goal of modulating its activity.

In addition to its potential as a drug target, WBP2 also has potential as a biomarker. The regulation of immune system and inflammatory processes is a critical part of human health, and changes in these processes can be indicative of underlying diseases. The ability of WBP2 to interact with multiple DNA-protein interfaces makes it a potential source of biomarkers for the diagnosis and treatment of immune and inflammatory disorders.

Overall, WBP2 is a protein that has the potential to be a drug target or biomarker, and its function is being studied extensively to determine its role in the regulation of the immune and inflammatory systems. Further research is needed to fully understand the unique mechanisms of WBP2 and its potential as a drug or biomarker.

Protein Name: WW Domain Binding Protein 2

Functions: Acts as transcriptional coactivator of estrogen and progesterone receptors (ESR1 and PGR) upon hormone activation (PubMed:16772533). In presence of estrogen, binds to ESR1-responsive promoters (PubMed:16772533). Required for YAP1 coactivation function on PGR activity (PubMed:16772533). Synergizes with WBP2 in enhancing PGR activity (PubMed:16772533). Modulates expression of post-synaptic scaffolding proteins via regulation of ESR1, ESR2 and PGR (By similarity)

The "WBP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WBP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1